Gland Pharma Limited (NSE:GLAND)

Gland Pharma Statistics

Total Valuation

Gland Pharma has a market cap or net worth of INR 317.80 billion. The enterprise value is 291.41 billion.

Market Cap	317.80B
Enterprise Value	291.41B

Important Dates

The next estimated earnings date is Monday, November 3, 2025.

Earnings Date	Nov 3, 2025
Ex-Dividend Date	Aug 14, 2025

Share Statistics

Gland Pharma has 164.76 million shares outstanding. The number of shares has increased by 0.03% in one year.

Current Share Class	164.76M
Shares Outstanding	164.76M
Shares Change (YoY)	+0.03%
Shares Change (QoQ)	-0.03%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	37.09%
Float	73.18M

Valuation Ratios

The trailing PE ratio is 41.26 and the forward PE ratio is 32.07. Gland Pharma's PEG ratio is 0.93.

PE Ratio	41.26
Forward PE	32.07
PS Ratio	5.56
PB Ratio	3.47
P/TBV Ratio	3.61
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	0.93

Enterprise Valuation

EV / Earnings	37.83
EV / Sales	5.09
EV / EBITDA	21.54
EV / EBIT	30.15
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.03
Debt / EBITDA	0.23
Debt / FCF	n/a
Interest Coverage	22.33

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	6.51%
Return on Capital Employed (ROCE)	n/a
Revenue Per Employee	13.15M
Profits Per Employee	1.77M
Employee Count	4,351
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Gland Pharma has paid 3.87 billion in taxes.

Income Tax	3.87B
Effective Tax Rate	33.44%

Stock Price Statistics

The stock price has increased by +17.46% in the last 52 weeks. The beta is 0.39, so Gland Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+17.46%
50-Day Moving Average	1,942.35
200-Day Moving Average	1,722.67
Relative Strength Index (RSI)	48.34
Average Volume (20 Days)	105,406

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Gland Pharma had revenue of INR 57.20 billion and earned 7.70 billion in profits. Earnings per share was 46.75.

Revenue	57.20B
Gross Profit	33.02B
Operating Income	9.66B
Pretax Income	11.57B
Net Income	7.70B
EBITDA	13.34B
EBIT	9.66B
Earnings Per Share (EPS)	46.75

Balance Sheet

The company has 29.52 billion in cash and 3.14 billion in debt, giving a net cash position of 26.38 billion or 160.14 per share.

Cash & Cash Equivalents	29.52B
Total Debt	3.14B
Net Cash	26.38B
Net Cash Per Share	160.14
Equity (Book Value)	91.51B
Book Value Per Share	555.41
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 57.73%, with operating and profit margins of 16.89% and 13.46%.

Gross Margin	57.73%
Operating Margin	16.89%
Pretax Margin	20.23%
Profit Margin	13.46%
EBITDA Margin	23.32%
EBIT Margin	16.89%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 18.00, which amounts to a dividend yield of 0.93%.

Dividend Per Share	18.00
Dividend Yield	0.93%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-0.03%
Shareholder Yield	0.90%
Earnings Yield	2.42%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2